AEON Bio (AEON): Price-to-Revenue Ratio

Brandmark of AEON Bio (AEON)

Price-to-sales dynamics demonstrate valuation volatility, where the level reflects the current magnitude of the metric. The financial position of AEON Biopharma (AEON) relies on shareholder investments, as operating income is not yet being generated. Drug development is accelerating through AI platforms that automate formula discovery. Innovations are focused on identifying new therapeutic properties of botulinum toxin to combat neurological pain.

AEON AEON Biopharma, Inc. P/S Multiple (07/04/2022 - 11/13/2026)

Analytical breakdowns for AEON Biopharma (AEON)

- current quotes and average value forecast:
Market Price aeonbiopharma.com|AEON - Price Target Chart
- stock exchange capitalization data:
Market Value AEON Bio|AEON - Total Company Value
- issuer book value statistics:
Net Asset Value per Share AEON Biopharma|AEON - Book Capitalization|Market Value to Equity Ratio aeonbiopharma.com|AEON - Cumulative Company Assets
- issuer credit burden and liquidity indicators:
Debt to Capital AEON Biopharma|AEON - Long-Term Debt to Capital|Short-Term Debt to Capital aeonbiopharma.com|AEON - Company Aggregate Debts|Debts to Book Value AEON Bio|AEON - Company Long-Term Debt|Short-Term Debt AEON Biopharma|Immediate Liquidity Ratio aeonbiopharma.com
- earnings and multiples data:
AEON - Net Income|Expected Net Income AEON Biopharma|AEON - P/E Multiple|Future Price to Earnings aeonbiopharma.com|AEON - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio AEON Bio|AEON - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months AEON Biopharma|AEON - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months aeonbiopharma.com|AEON - Earnings growth in current year|Expected earnings per share trend next year AEON Biopharma
- issuer revenue and sales details:
AEON - Revenue and Sales Volume|Projected Sales Volume aeonbiopharma.com|AEON - Price-to-Revenue Ratio|Forward Price to Sales AEON Bio
General company analysis:AEON - AEON Biopharma Inc.
Mass-produced product of AEON Biopharma

The P/S ratio compares the market value of AEON Biopharma (AEON) to its annual sales volume, measuring the premium the market is willing to pay per unit of revenue. Analyzing the price-to-sales trend allows for an assessment of the efficiency of diversified neurotoxin supply chains, determining whether the current price represents a discounted asset or is a result of business stagnation.

Competitors of AEON Biopharma

JAZZ - Price to Sales|Price-to-Revenue Ratio Cytokinetics, Incorporated CYTK|PTC Therapeutics Inc - Price-to-Revenue Ratio|SRRK - Price-to-Revenue Ratio|Price to Sales Centessa Corp|DYN: P/S Multiple|Price-to-Revenue Multiple edgewisetx.com EWTX|Market Cap to Revenue RAPP|Price to Sales Alumis Inc ALMS|P/S Multiple ZVRA|P/S Multiple Contineum Corp (CTNM)|P/S Multiple LRMR (Larimar Therapeutics)|Capricor Therapeutics Inc. (CAPR) - Price to Sales|TRDA - Price-to-Revenue Ratio|Price to Sales Channel Therapeutics Inc.|medicinova.com (MNOV) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio SER|Market Cap to Revenue BTAI|PMN: Market Capitalization-to-Revenue Ratio|P/S Multiple APUS|Price-to-Revenue Ratio NLSP (nlspharma.com)|P/S Multiple BNOX (Bionomics)|Price-to-Revenue Coefficient fsdpharma.com (HUGE)|RETA - Price-to-Revenue Ratio